– accelerating research, innovation and development.
Despite the talk about the modern digitalized laboratory, many organizations are still relying on legacy R&D software. As a consequence, data is lost, fragmented and siloed. Time is lost. Together, we need to mend the disjointed data landscape of R&D.
For over 30 years IDBS has helped R&D organizations achieve faster scientific breakthroughs by providing innovative software focusing on scientific workflows and systems integration to deliver the analysis and insights that streamline operations and accelerate science.
We provide integrated workflows and processes across the business to improve lab efficiency and foster collaboration.
Our platform is seamlessly integrated with your data ecosystem to break down data silos and promote knowledge transfer.
You will benefit from high-quality, contextualized data that speeds up decision-making and provides insights that enable you to optimize processes and remove operational inefficiencies.
The best-in-class platform for scientific research and innovation
For research and innovation in all industries
The world’s first BioPharmaceutical Lifecycle Management system
Accelerating Biopharmaceutical development
We offer a complete ecosystem for your research, innovation and development. An enterprise-wide SaaS cloud platform that is enhanced by on-site installations when needed – to provide one integrated scientific data management system for R&D. We provide our customers with a comprehensive set of tools, adapted to meet the evolving business needs of any market – now and in the future.
IDBS platform eliminates the need for many different disparate lab informatics systems, such as ELN, LIMS, LES and SDMS by providing the rich capabilities of all of these technologies in a single platform.
Everything you and your scientists need – in one place.
Our modules are designed to provide your R&D organization, and your scientists, with an intuitive, easy-to-use, and comprehensive set of tools.
Each module integrates seamlessly together with your workflows and instruments to deliver the best user experience and form an enterprise-ready, scientific informatics platform.
Create and manage samples, materials and equipment with your workflow
Plan and coordinate work between teams
Design and execute compliant laboratory workflows and processes
Capture and manage experimental and procedural data with rich context
Integrate systems and equipment
Manage internal and external collaborations
Design, register and develop chemical and biochemical materials
Run your experiment in a lab.
Analyze the data working from home.
Share it and collaborate instantly across the globe.
Our platform securely connects people, instruments, and workflows giving you more time to make breakthrough discoveries.
IDBS E-WorkBook is the world’s best-in-class informatics platform for scientific research and development. It is a flexible R&D software that meets the demands of your particular industry, the needs of the various business units in your organization today, and that can rapidly adapt and scale to meet whatever requirements you may have tomorrow.
Meet IDBS Polar, the world’s first BioPharma Lifecycle Management system (BPLM) that eliminates repetitive manual tasks, allowing you to efficiently execute your processes while curating the data you need to accelerate time to market by tackling the biggest challenges in process design, optimization, scale-up and technology transfer.
SaaS technology to support collaboration across global networks and internal stakeholders
Flexible yet structured workflows delivering contextualized data
Rich user experience improving user adoption and productivity
Comprehensive APIs simplifies integration to key lab technologies and instruments
Automate data flow and processes to remove bottlenecks, errors and wasted time
Powerful analytical tools for insights, forecasting and reporting
Data stored in most common formats to future-proof your data
Accredited with the highest standards for SaaS, including SOC 2 Type 2
18 of the world’s top 20 pharma companies use IDBS
Reduction in errors in regulated or compliant environments
Additional productivity increase per user
Improvement in speed of decision making
“We are rapidly reducing data handling time for a growing number of routine assays allowing our scientists to spend a higher portion of their time in the laboratory.”
Phil Bland-Ward, Chief Scientific Officer
Crescendo Biologics
For over 30 years we have worked with world-leading research organizations to deliver best-in-class R&D informatic solutions, giving us unmatched market insight and understanding of unique domain-specific processes.
Celyad Oncology chooses IDBS to facilitate its data management and support future R&D data needs. Celyad Oncology is a clinical-stage biotech company focused on the discovery and development of chimeric antigen receptor T-cell (CAR-T) therapies for cancer. It evaluates…
3B Pharmaceuticals has become a leading player in the discovery and development of innovative radiopharmaceutical cancer medicines and diagnostics. Building on its core expertise in peptide drug discovery 3BP has developed a broad product pipeline of which several programs…
Goldfinch Bio is a cutting edge, fast-growing biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new…
Sealy Inc. improves efficiency and promotes corporate compliance with E-WorkBook, leading to significant productivity gains across the Company. The challenge Previously using paper lab notebooks, Sealy Inc. found that its data was not being fully utilized and the company…
IDBS, a leading R&D technology and solutions provider and Tableau, the world’s leading analytics platform, announced a strategic partnership to integrate Tableau into the IDBS suite of products. The collaboration will be based on embedding Tableau’s visual and analytics capabilities into the IDBS product offerings.
There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.
In a recent Forbes article, Danaher’s Chief Science officer, Jose-Carlos Gutierrez-Ramos, described the impact of the COVID-19 pandemic as follows:“I believe the biopharma business model has fundamentally changed.
The public consciousness has been flooded with awareness of the previously niche concerns of quality control in drug manufacturing.
